Inspire Advisors’s Celldex Therapeutics CLDX Stock Holding History

Inspire Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-29	Closed	-$1K	–	205
2020 Q4	$1K	Buy	+29	New	+$522	﹤0.01%	726

Other funds holding CLDX

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Inspire Advisors's CLDX Position: Q1 2021 in Review

Inspire Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2021, closing a stake of 29 shares — an estimated $1K sold.

Inspire Advisors first reported a position in CLDX in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 115 funds tracked by Wall St. Rank hold CLDX as of Q1 2021.

Inspire Advisors reported no remaining Celldex Therapeutics position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 29 Celldex Therapeutics shares in Q1 2021, an estimated $1K.
Inspire Advisors first reported a position in Celldex Therapeutics in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Celldex Therapeutics position peaked at $1K in Q4 2020.
115 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.